己酮可可碱在帕金森病中的应用
Oxpentifylline in Parkinson's disease.
作者信息
Godwin-Austen R B, Twomey J A, Hanks G, Higgins J
出版信息
J Neurol Neurosurg Psychiatry. 1980 Apr;43(4):360-4. doi: 10.1136/jnnp.43.4.360.
Abstract
The effects of oxpentifylline were assessed in a double-blind trial in 11 patients with Parkinson's disease already under treatment. No significant improvement was noted. Eight patients developed involuntary movements or a worsening of movements if already present. The significance of this unexpected finding is discussed.
摘要
在一项双盲试验中，对11名正在接受治疗的帕金森病患者使用己酮可可碱的效果进行了评估。未观察到显著改善。8名患者出现了不自主运动，或者如果原本就存在运动问题，则运动情况恶化。本文讨论了这一意外发现的意义。
相似文献
1
Oxpentifylline in Parkinson's disease.己酮可可碱在帕金森病中的应用
J Neurol Neurosurg Psychiatry. 1980 Apr;43(4):360-4. doi: 10.1136/jnnp.43.4.360.
2
Oxpentifylline in dementia: a controlled study.
Arch Gerontol Geriatr. 1987 Apr;6(1):19-26. doi: 10.1016/0167-4943(87)90035-5.
3
The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.长效多巴胺受体激动剂卡麦角林用于早期帕金森病：一项为期5年的双盲、左旋多巴对照研究的最终结果
CNS Drugs. 2004;18(11):733-46. doi: 10.2165/00023210-200418110-00003.
4
AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.AFQ056 在伴有左旋多巴诱导运动障碍的帕金森病患者中的 13 周、随机、剂量发现研究。
Mov Disord. 2013 Nov;28(13):1838-46. doi: 10.1002/mds.25561. Epub 2013 Jul 12.
5
Effect of oxpentifylline on blood viscosity and cerebral blood flow in man.己酮可可碱对人体血液粘度和脑血流量的影响。
Br J Clin Pharmacol. 1989 Oct;28(4):488-92. doi: 10.1111/j.1365-2125.1989.tb03531.x.
6
Oxpentifylline treatment of venous ulcers of the leg.己酮可可碱治疗腿部静脉溃疡
BMJ. 1990 Apr 14;300(6730):972-5. doi: 10.1136/bmj.300.6730.972.
7
Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.帕金森病患者中，玛伐谷氨酸（AFQ056）与增加左旋多巴剂量联合使用。
Int J Neurosci. 2016;126(1):20-4. doi: 10.3109/00207454.2013.841685. Epub 2015 Aug 18.
8
Pharmacologic treatment of intermittent claudication.
Surgery. 1982 Dec;92(6):966-71.
9
[Treatment of circulation disorders with pentoxifylline. A double-blind study with Trental].
Med Monatsschr. 1977 Oct;31(10):467-72.
10
Treatment of Parkinson's disease with proglumide, a CCK antagonist.
Neurology. 1991 May;41(5):749-50. doi: 10.1212/wnl.41.5.749.
本文引用的文献
1
Flicker fusion frequency; background and applications.闪烁融合频率；背景及应用
Physiol Rev. 1952 Jul;32(3):349-78. doi: 10.1152/physrev.1952.32.3.349.
2
[Conservative treatment of chronic arterial occlusive disease using Trental].
Med Monatsschr. 1972 Mar;26(3):127-31.
3
Is adenylate cyclase the dopamine receptor?腺苷酸环化酶是多巴胺受体吗？
Med Biol. 1974 Oct;52(5):350-3.
4
Effects of L-dopa in Parkinson's disease.
Lancet. 1969 Jul 26;2(7613):165-8. doi: 10.1016/s0140-6736(69)91417-2.
5
6
Critical flicker frequency (CFF) and psychotropic drugs in normal human subjects-a review.正常人体受试者的临界闪烁频率（CFF）与精神药物——综述
Psychopharmacologia. 1976 May 28;47(2):175-82. doi: 10.1007/BF00735818.
7
[Effect of Pentoxyphylline on blood viscosity and erythrocyte surface].
Med Welt. 1975 Oct 24;26(43):1977-9.
8
Effects of lisuride and LSD on cerebral monoamine systems and hallucinosis.利苏瑞ide和麦角酸二乙酰胺对脑单胺系统及幻觉症的影响。 （注：原文中“lisuride”可能拼写有误，常见的是“lisuride”，暂按此翻译，若有误请根据正确内容调整）
Nature. 1978 Mar 16;272(5650):278-80. doi: 10.1038/272278a0.
9
Effects of bromocriptine on central dopaminergic receptors.溴隐亭对中枢多巴胺能受体的影响。
Life Sci. 1976 Jul 15;19(2):225-31. doi: 10.1016/0024-3205(76)90394-5.
10
Effect of some phosphodiesterase inhibitors on central dopamine mechanisms.
Eur J Pharmacol. 1976 Jul;38(1):31-8. doi: 10.1016/0014-2999(76)90198-9.
Zotero 插件